We are live on ! Find out more
KALV

KalVista Pharmaceuticals
KALV

Delisted

KALV was delisted on the 10th of June, 2026.

Back to rankings

93 hedge funds and large institutions have $459M invested in KalVista Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 46 increasing their positions, 22 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

109% more repeat investments, than reductions

Existing positions increased: 46 | Existing positions reduced: 22

90% more call options, than puts

Call options by funds: $21.3M | Put options by funds: $11.3M

33% more funds holding in top 10

Funds holding in top 10: 3 → 4 (+1)

31% more capital invested

Capital invested by funds: $349M → $459M (+$109M)

2.9% more ownership

Funds ownership: 105.42% → 108.32% (+2.9%)

8% less funds holding

Funds holding: 101 → 93 (-8)

36% less first-time investments, than exits

New positions opened: 14 | Existing positions closed: 22

Holders
93
Holders Change
-8
Holders Change %
-7.92%
% of All Funds
1.36%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.06%
New
14
Increased
46
Reduced
22
Closed
22
Calls
$21.3M
Puts
$11.3M
Net Calls
+$10.1M
Net Calls Change
+$3.39M

Top Buyers

Rank Fund Capital Flow
1
VA
VR Adviser
New York
+$10.7M
2
Morgan Stanley
Morgan Stanley
New York
+$6.32M
3
BlackRock
BlackRock
New York
+$5.43M
4
FLSM
Frazier Life Sciences Management
California
+$3.49M
5
WP
Woodline Partners
California
+$3.16M

Top Sellers

Rank Fund Capital Flow
1
LGM
Logos Global Management
California
-$8.67M
2
MB
MPM BioImpact
Massachusetts
-$5.57M
3
First Manhattan
First Manhattan
New York
-$3.78M
4
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$3.2M
5
OM
Opaleye Management
Massachusetts
-$3.18M
Name Holding Trade Value Shares
Change 		Change in
Stake
ECM
101
ExodusPoint Capital Management
New York
– -$331K -34,393 Closed
BFM
102
Boothbay Fund Management
New York
– -$297K -30,790 Closed
AA
103
ALPS Advisors
Colorado
– -$244K -25,338 Closed
AG
104
Algert Global
California
– -$224K -23,250 Closed
PAM
105
Panagora Asset Management
Massachusetts
– -$221K -22,941 Closed
Group One Trading
106
Group One Trading
Illinois
– -$127K -13,955 Closed
Bank of Montreal
107
Bank of Montreal
Ontario, Canada
– -$110K -10,807 Closed
SO
108
STRS Ohio
Ohio
– -$104K -10,800 Closed
PCM
109
Prelude Capital Management
New York
– -$103K -10,738 Closed
JF
110
Jump Financial
Illinois
– -$98.2K -10,200 Closed
Simplex Trading
111
Simplex Trading
Illinois
– -$80.2K -8,810 Closed
N
112
Natixis
France
– -$48.1K -5,000 Closed
QT
113
Quantbot Technologies
New York
– -$30.8K -3,200 Closed
AF
114
Allworth Financial
California
– -$261 -27 Closed
NFSG
115
Newbridge Financial Services Group
Florida
– -$241 -25 Closed
1 2 3 4
5

KALV Hedge Fund Activity: Q4 2023 in Review

93 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in KalVista Pharmaceuticals (KALV) for Q4 2023, worth a combined $459M — up 31% from $349M a quarter earlier.

Sellers outnumbered buyers: 22 funds closed out of KALV and 14 opened new positions — a net loss of 8 holders — while 22 trimmed existing stakes and 46 added.

The largest buyer was VR Adviser, adding an estimated $10.7M. The largest seller was Logos Global Management, exiting entirely with an estimated $8.67M sold.

  • 93 institutional investors held KalVista Pharmaceuticals (KALV) as of Q4 2023, down from 101 in Q3 2023.
  • Funds reported $459M of KalVista Pharmaceuticals stock for Q4 2023, up 31% quarter-over-quarter.
  • 14 funds opened new KalVista Pharmaceuticals positions in Q4 2023 and 22 closed out, a net change of -8 holders.
  • The largest KalVista Pharmaceuticals buyer in Q4 2023 was VR Adviser, an estimated $10.7M added.
  • The largest KalVista Pharmaceuticals seller in Q4 2023 was Logos Global Management, an estimated $8.67M sold.

Based on aggregated 13F filings for Q4 2023.